| Literature DB >> 34269807 |
Lona Mody1,2, Kyle J Gontjes1,3, Marco Cassone1, Kristen E Gibson1, Bonnie J Lansing1, Julia Mantey1, Mohammed Kabeto1, Andrzej Galecki1,4, Lillian Min1,2.
Abstract
Importance: Multidrug-resistant organisms (MDROs) can cause significant morbidity and mortality. Preventing MDROs can reduce the risk of subsequent transmission and infection. Objective: To determine whether a multicomponent infection prevention intervention can reduce MDRO prevalence in nursing homes (NHs). Design, Setting, and Participants: This cluster randomized clinical trial of a multicomponent intervention was conducted in 6 NHs in Michigan from September 2016 to August 2018. Three NHs adopted a multicomponent intervention, while 3 control NHs continued without investigator intervention. Study visits were conducted at baseline; days 7, 14, 21, and 30; and monthly thereafter for up to 6 months or discharge. Visits included clinical data collection and MDRO surveillance culturing of multiple body sites and high-touch surfaces in patient rooms. Any patients who provided informed consent within 14 days of admission to the NH were enrolled in this study. Non-English speakers and patients receiving hospice care were ineligible. Analysis was performed from November 2018 to February 2020. Interventions: Intervention NHs adopted a multicomponent intervention that included enhanced barrier precautions, chlorhexidine bathing, MDRO surveillance, environmental cleaning education and feedback, hand hygiene promotion, and health care worker education and feedback. Control nursing homes continued standard care practices. Main Outcomes and Measures: The primary outcome, presence of MDROs, was measured longitudinally in the patient and room environment and was evaluated using generalized mixed effect models. The secondary outcome, time to new MDRO acquisition, was assessed using Cox proportional hazard models.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34269807 PMCID: PMC8285736 DOI: 10.1001/jamanetworkopen.2021.16555
Source DB: PubMed Journal: JAMA Netw Open ISSN: 2574-3805
Overview of Multicomponent Intervention
| Intervention component | Intervention target | Intervention facilities (multicomponent intervention) | Control facilities (usual care) |
|---|---|---|---|
| Enhanced barrier precautions for high-risk patients | Enrolled patients with high risk | Enhanced barrier precautions (gowns and gloves) for high-risk patients. | Standard infection prevention practices. |
| Chlorhexidine bathing | Enrolled patients | Chlorhexidine bathing. | No chlorhexidine bathing. |
| Surveillance: MDRO and any infections | Nursing home | Patient and environment cultures at baseline; days 7, 14, and 30; and then monthly thereafter until 6 mo or discharge; monthly data feedback was provided. | Patient and environment cultures at baseline; days 7, 14, and 30; and then monthly thereafter until 6 mo or discharge; no feedback provided |
| Environmental cleaning improvement | Nursing home | Educational in-services and checklists for environmental service staff; monthly data feedback was provided to staff. | Standard environmental cleaning practices; no feedback was provided. |
| Hand hygiene promotion | Enrolled patients and HCWs | Patients hand hygiene education on enrollment; HCWs received hand hygiene education and pocket-size alcohol-based hand sanitizer. | No patient or HCW hand hygiene education; no hand sanitizer was distributed. |
| HCW education and monthly feedback | Nursing home | Interactive infection prevention education | No education; study team responded to any concerns when asked for advice. |
Abbreviations: HCW, health care worker; MDRO, multidrug-resistant organism.
Figure. Participant Enrollment Flowchart
Patients were enrolled within 14 days of arrival at the nursing home.
Characteristics of Patients Receiving Postacute Care on Enrollment
| Characteristic | No. (%) | |
|---|---|---|
| Intervention (n = 113) | Control (n = 132) | |
| Age, mean (SD), y | 71.6 (13.6) | 73.2 (13.6) |
| Sex | ||
| Men | 48 (42.5) | 63 (47.7) |
| Women | 65 (57.5) | 69 (52.3) |
| Race | ||
| Non-Hispanic White | 49 (43.4) | 83 (63.4) |
| African American | 64 (56.6) | 48 (36.6) |
| Antibiotic use in past 30 d | 63 (58.3) | 68 (54.8) |
| Charlson Comorbidity Index score, median (IQR) | 2 (1-3) | 2 (1-4) |
| Physical Self-Maintenance Scale score, median (IQR) | 12 (10.0-15.5) | 13.5 (10.0-17.0) |
| Ambulation | 49 (43.4) | 71 (54.2) |
| Dressing | 47 (41.6) | 78 (59.5) |
| Bathing | 45 (39.8) | 69 (52.3) |
| Toileting | 30 (26.6) | 46 (35.1) |
| Grooming | 23 (20.4) | 39 (29.6) |
| Feeding | 3 (2.7) | 7 (5.3) |
| Device use on enrollment | 10 (8.9) | 19 (14.4) |
| Feeding tube | 2 (1.8) | 5 (3.8) |
| Urinary catheter | 8 (7.1) | 15 (11.4) |
| Percutaneously inserted central line | 6 (5.3) | 7 (5.3) |
| History of MDRO | ||
| MRSA | 4 (3.7) | 3 (2.5) |
| VRE | 1 (0.9) | 1 (0.8) |
| R-GNB | 2 (1.9) | 4 (3.3) |
| Open wounds on enrollment | 15 (13.5) | 19 (15.0) |
| Admitted from hospital | 109 (99.1) | 126 (98.4) |
| Length of preadmission hospitalization >14 d | 13 (11.6) | 10 (7.6) |
| Anticipated short stay | 108 (96.4) | 123 (93.9) |
| Follow-up, median (IQR), d | 14 (6-22) | 14 (7-27) |
Abbreviations: IQR, interquartile range; MDRO, multidrug-resistant organism; MRSA, methicillin-resistant Staphylococcus aureus; R-GNB, resistant gram-negative bacilli; VRE, vancomycin-resistant enterococci.
Owing to data missing on admission sample sizes were race/ethnicity, 244 patients; antibiotic use in past 30 days, 232 patients; physical self-maintenance scale score, 242 patients; ambulation, 244 patients; dressing, 244 patients; toileting, 244 patients; feeding, 244 patients; history of MRSA, 227 patients; history of VRE, 229 patients; history of R-GNB, 225 patients; open wounds on enrollment, 238 patients; admitted from hospital, 238 patients; length of preadmission hospitalization longer than 14 days, 244 patients; and anticipated short-stay patient, 243 patients.
Functional disabilities are defined as ambulation: ambulates with assistance of another person, uses a wheelchair with help getting in and out, or cannot move without help; dressing: requires at least moderate assistance with dressing; bathing: unable to independently bathe more than hands and face; toileting: soiling or wetting more than once a week; grooming: regularly needs at least moderate assistance or supervision in grooming; and feeding: eats with moderate assistance and is untidy.
Effect of Multicomponent Intervention on MDRO Outcomes
| Analysis | OR (95% CI) | |||
|---|---|---|---|---|
| Any MDRO | MRSA | VRE | R-GNB | |
| Unadjusted model | ||||
| Patient colonization | 0.51 (0.25-1.05) | 0.59 (0.09-3.78) | 0.51 (0.22-1.21) | 0.67 (0.35-1.26) |
| Environment contamination | 0.59 (0.35-0.98) | 0.57 (0.28-1.16) | 0.49 (0.25-0.95) | 0.74 (0.44-1.24) |
| Adjusted model | ||||
| Patient colonization | 0.57 (0.29-1.14) | 0.61 (0.09-4.32) | 0.62 (0.28-1.38) | 0.71 (0.37-1.37) |
| Environment contamination | 0.57 (0.35-0.94) | 0.62 (0.30-1.29) | 0.50 (0.26-0.98) | 0.63 (0.37-1.07) |
| Unadjusted model | 0.56 (0.33-0.97) | 0.39 (0.14-1.06) | 0.49 (0.25-0.95) | 0.70 (0.44-1.14) |
| Adjusted model | 0.58 (0.35-0.98) | 0.44 (0.16-1.20) | 0.53 (0.27-1.02) | 0.67 (0.41-1.09) |
Abbreviations: MDRO, multidrug-resistant organism; MRSA, methicillin-resistant Staphylococcus aureus; OR, odds ratio; R-GNB, resistant Gram-negative bacilli; VRE, vancomycin-resistant enterococci.
P < .05.
Adjusted for age, sex, race/ethnicity, functional status, and device use.
Adjusted for multilevel data by considering 2 random effects (dyads clustered within visits and patient vs environment within each dyad). Analyses included 245 dyads with 1586 total visits.
Effect of Multicomponent Intervention on New MDRO Acquisition Rates
| Organism | Intervention group | Control group | Patient covariate–adjusted | Patient- and environment-level adjusted | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| New acquisitions, No. | Follow-up, patient-days | New acquisition rate per 1000 patient-days (95% CI) | New acquisitions, No. | Follow-up, patient-days | New acquisition rate per 1000 patient-days (95% CI) | HR (95% CI) | HR (95% CI) | |||
| Any MDRO (n = 195 patients) | 47 | 1296 | 36.3 (27.2-48.3) | 67 | 1568 | 42.7 (33.6-54.3) | 0.91 (0.66-1.27) | .59 | 0.99 (0.66-1.48) | .97 |
| MRSA (n = 168 patients) | 4 | 1667 | 2.4 (0.9-6.4) | 17 | 2129 | 8.0 (5.0-12.8) | 0.20 (0.04-1.09) | .06 | 0.19 (0.04-1.07) | .06 |
| VRE (n = 148 patients) | 13 | 1553 | 8.4 (4.9-14.4) | 17 | 1898 | 9.0 (5.6-14.4) | 0.84 (0.46-1.53) | .57 | 0.90 (0.49-1.64) | .73 |
| R-GNB (n = 163 patients) | 21 | 1558 | 13.5 (8.8-20.7) | 27 | 1945 | 13.9 (9.5-20.2) | 1.14 (0.73-1.78) | .57 | 1.17 (0.73-1.85) | .52 |
Abbreviations: HR, hazard ratio; MDRO, multidrug-resistant organism; MRSA, methicillin-resistant Staphylococcus aureus; R-GNB, resistant gram-negative bacilli; VRE, vancomycin-resistant enterococci.
95% CIs were calculated using a quadratic approximation to the Poisson log-likelihood for the log rate estimate.
Multivariable Cox regression model was adjusted for age, sex, race/ethnicity, functional status, and device use.
The patient- and environment-level adjusted model added visit-level patient room environment contamination to the multivariable Cox regression model to control for the influence of the room environment on MDRO acquisition.